Wall Street Zen downgraded shares of Immunocore (NASDAQ:IMCR – Free Report) from a buy rating to a hold rating in a research report report published on Tuesday.
IMCR has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.71.
Read Our Latest Stock Report on Immunocore
Immunocore Stock Up 1.3%
Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million for the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. On average, equities research analysts predict that Immunocore will post 0.06 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Leonteq Securities AG purchased a new position in shares of Immunocore during the fourth quarter worth $30,000. Harbour Investments Inc. raised its holdings in shares of Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Immunocore in the 4th quarter valued at $47,000. Arax Advisory Partners lifted its stake in Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after acquiring an additional 1,042 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after acquiring an additional 1,286 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.
Immunocore Company Profile
Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.
The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.
Recommended Stories
- Five stocks we like better than Immunocore
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
